|1.||Honkanen, Richard E: 2 articles (08/2013 - 01/2007)|
|2.||Dean, Nicholas M: 1 article (08/2013)|
|3.||Musiyenko, Alla: 1 article (08/2013)|
|4.||Theobald, Benjamin: 1 article (08/2013)|
|5.||Urban, Gudrun: 1 article (08/2013)|
|6.||Huang, Xizhong: 1 article (08/2013)|
|7.||Bonness, Kathy: 1 article (08/2013)|
|8.||Andrews, Joel F: 1 article (08/2013)|
|9.||Owonikoko, Taofeek K: 1 article (05/2013)|
|10.||Sun, Shi-Yong: 1 article (05/2013)|
09/01/1998 - "In a second study with isolated rabbit cardiomyocytes, the effect of fostriecin pretreatment was assessed by measuring changes in cell osmotic fragility during simulated ischemia. "
09/01/1998 - "Fostriecin, a potent inhibitor of PP2A, was administered to isolated rabbit hearts starting either 15 minutes before or 10 minutes after the onset of a 30-minute period of regional ischemia and continuing until the onset of reperfusion. "
09/01/1998 - "Fostriecin, a potent inhibitor of PP2A, can protect the rabbit heart from infarction even when administered after the onset of ischemia. "
01/01/1998 - "Protein phosphatase inhibitors calyculin A and fostriecin protect rabbit cardiomyocytes in late ischemia."
09/01/1998 - "Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia."
10/15/2000 - "Mutations in genes encoding PR65/A subunits have been identified in several different human cancers and the PP2A inhibitor, termed fostriecin, is being tested as an anticancer drug. "
08/01/1986 - "A human tumor cloning assay was utilized to evaluate the antineoplastic activity of the novel antitumor antibiotic fostriecin (CI-920). "
08/01/1986 - "In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay."
01/01/1985 - "CI-920 was less active or inactive against the murine solid tumors tested. "
04/01/1994 - "Fostriecin is an antitumor antibiotic with marked activity against ovarian, breast, and lung cancer cell lines in the human tumor clonogenic assay. "
02/01/1989 - "The histological effects of flavone acetic acid and fostriecin were indistinguishable from those of recombinant human tumour necrosis factor alpha. "
02/01/1989 - "In contrast, flavone acetic acid, fostriecin and homoharringtonine caused extensive necrosis of tumours after 24 h, and each delayed the growth of advanced subcutaneous tumours by at least 10 days when administered as a single dose. "
02/01/1989 - "Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice."
07/01/1992 - "Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in MOLT-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation."
|2.||Type II DNA Topoisomerases (Topoisomerase II)
|4.||Teniposide (VM 26)
|5.||DNA (Deoxyribonucleic Acid)
|7.||Topoisomerase II Inhibitors
|8.||Reduced Folate Carrier Protein
|9.||Protein Phosphatase 2 (Protein Phosphatase 2A)